trending Market Intelligence /marketintelligence/en/news-insights/trending/vjTUYrPtWGBSrvBAifQnuA2 content esgSubNav
In This List

Gilead to pay Kyverna $17.5M upfront in autoimmune disease partnership

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Gilead to pay Kyverna $17.5M upfront in autoimmune disease partnership

Gilead Sciences Inc. has signed a licensing agreement with Kyverna Therapeutics to develop T cell therapies to treat autoimmune diseases.

Kyverna will provide its synthetic T platform with a technology called synNotch, which was developed by Gilead's Kite Pharma unit.

Gilead will pay an upfront fee of $17.5 million, and Kyverna will be eligible for up to $570 million in development and commercialization milestones.

Kyverna will handle research and clinical studies, and Gilead will have an option to advance clinical development and commercialization efforts for any candidates that emerge from the partnership.